Logo image of GALT

GALECTIN THERAPEUTICS INC (GALT) Stock Fundamental Analysis

NASDAQ:GALT - Nasdaq - US3632252025 - Common Stock - Currency: USD

2.42  -0.87 (-26.44%)

After market: 2.44 +0.02 (+0.83%)

Fundamental Rating

0

GALT gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of GALT have multiple concerns. GALT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GALT has reported negative net income.
GALT had a negative operating cash flow in the past year.
In the past 5 years GALT always reported negative net income.
In the past 5 years GALT always reported negative operating cash flow.
GALT Yearly Net Income VS EBIT VS OCF VS FCFGALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -475.52%, GALT is not doing good in the industry: 96.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -475.52%
ROE N/A
ROIC N/A
ROA(3y)-203.75%
ROA(5y)-152.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GALT Yearly ROA, ROE, ROICGALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GALT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GALT Yearly Profit, Operating, Gross MarginsGALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, GALT has more shares outstanding
The number of shares outstanding for GALT has been increased compared to 5 years ago.
Compared to 1 year ago, GALT has a worse debt to assets ratio.
GALT Yearly Shares OutstandingGALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GALT Yearly Total Debt VS Total AssetsGALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

GALT has an Altman-Z score of -86.27. This is a bad value and indicates that GALT is not financially healthy and even has some risk of bankruptcy.
GALT has a worse Altman-Z score (-86.27) than 96.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -86.27
ROIC/WACCN/A
WACCN/A
GALT Yearly LT Debt VS Equity VS FCFGALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 0.08 indicates that GALT may have some problems paying its short term obligations.
GALT has a Current ratio of 0.08. This is amonst the worse of the industry: GALT underperforms 97.67% of its industry peers.
GALT has a Quick Ratio of 0.08. This is a bad value and indicates that GALT is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.08, GALT is doing worse than 97.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
GALT Yearly Current Assets VS Current LiabilitesGALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.70% over the past year.
EPS 1Y (TTM)2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.50% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.45%
EPS Next 2Y-22.05%
EPS Next 3Y4.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GALT Yearly Revenue VS EstimatesGALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 100M 200M 300M 400M 500M
GALT Yearly EPS VS EstimatesGALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GALT. In the last year negative earnings were reported.
Also next year GALT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GALT Price Earnings VS Forward Price EarningsGALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GALT Per share dataGALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.05%
EPS Next 3Y4.5%

More info and screens

0

5. Dividend

5.1 Amount

GALT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALECTIN THERAPEUTICS INC

NASDAQ:GALT (6/20/2025, 8:00:00 PM)

After market: 2.44 +0.02 (+0.83%)

2.42

-0.87 (-26.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners15.78%
Inst Owner Change-1.64%
Ins Owners19.77%
Ins Owner Change1.94%
Market Cap153.16M
Analysts43.33
Price Target11.22 (363.64%)
Short Float %20.22%
Short Ratio48.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.02%
Min EPS beat(2)-16.42%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)-0.18%
Min EPS beat(4)-22.55%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-4.04%
EPS beat(12)7
Avg EPS beat(12)2%
EPS beat(16)10
Avg EPS beat(16)5.66%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.52%
EPS NY rev (1m)0%
EPS NY rev (3m)3.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS-1.77
TBVpS-1.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -475.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.75%
ROA(5y)-152.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -86.27
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.05%
EPS Next Y-19.45%
EPS Next 2Y-22.05%
EPS Next 3Y4.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.47%
OCF growth 3YN/A
OCF growth 5YN/A